Stockreport

IDEAYA Biosciences Announces First-Patient-In for Phase 1 Trial of IDE574, a Potential First-In Class Dual Inhibitor of KAT6/7 to Target Multiple Solid Tumor Indications, including Breast,...

IDEAYA Biosciences, Inc.  (IDYA) 
Last ideaya biosciences, inc. earnings: 3/24 06:00 am Check Earnings Report
PDF April 6, 2026 /PRNewswire/ -- IDEAYA Biosciences, Inc. (NASDAQ: IDYA), a leading precision medicine oncology company, today announced that the first patient has been enr [Read more]